Global Influenza Vaccines Market and Forecasts 2024 – 2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	310 Pages	DPI Research	January, 2024	DPI18448450

Best Price Guarantee
Price	from $3,500
Length	310 Pages
Publisher	DPI Research
Published Date	January, 2024
SKU	DPI18448450

Global Influenza Vaccines Market and Forecasts 2024 – 2032

The global influenza vaccines market size was valued at USD 7.8 Billion in 2023 and is likely to reach USD 13.7 Billion in 2032, expanding at a CAGR 7.2% during the forecast period.

Several factors are contributing to the growth of the influenza vaccines market. Here are some key factors:

Increasing Awareness and Education
Government Initiatives and Vaccination Programs
Rising Incidence of Influenza
Advancements in Vaccine Technology
Increased Healthcare Spending
Expanding Target Population
Globalization and Travel
Growing Geriatric Population
Public Health Preparedness
Collaborations and Partnerships
Regulatory Support

“Global Influenza Vaccines Market and Forecasts 2024 – 2032” presents an in-depth assessment of the global influenza vaccines market dynamics, opportunities, future road map, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook in the global influenza vaccines market. The report also provides up-to-date historical market size data for the period 2018 – 2023 and an illustrative forecast to 2032 covering key market aspects like market value, volume analysis, and trends for influenza vaccines globally.

The report contains a deep analysis of the global influenza vaccines market with size in terms of both value and volume. The report provides a clear insight into current and future developments of the global influenza vaccines market. The report also explores a detailed analysis of the children and adults vaccinated with influenza vaccines globally from 2018-

2023 and forecasts to 2032. It provides essential insights into influenza vaccines market revenue for the top 27 regional and national, and forecast until 2032.

Key trends in terms of collaboration deals, merger & acquisitions, distribution, exclusive and licensing agreement are analyzed with details. The report also offers detailed information about the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase. The report also investigates detailed insights about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU, and Japan. The report also delivers a detailed assessment of the latest happenings in the influenza vaccines market globally. The report also examines the main market growth driving and challenges forces and also gives an all-round future outlook through 2032.

The report concludes with the profiles of the key players in the global influenza vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, promising vaccines in the clinical development, influenza vaccines sales value analysis, and recent development.

Other emerging players are making novel technology-based vaccines that are likely to affect the market share during the forecast period. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with phase, platform technology, and recent development.

The report will serve as a source for a 360-degree analysis in which various models will be thoroughly integrated. After a thorough study of the historical and current growth parameters, the growth prospects of the global influenza vaccines market are determined with utmost precision.

Key and Emerging Players in the Global Influenza Vaccines Market are Listed Below:

1. Sanofi Pasteur
2. GlaxoSmithKline (GSK)
3. Seqirus (CSL Limited)
4. AstraZeneca
5. Mylan(Viatris)
6. BioDiem
7. Novavax
8. Medicago
9. Moderna Inc
10. Pneumagen
11. Daiichi–Sankyo
12. Altimmune
13. FluGen
14. Imutex
15. EpiVax
16. Osivax
17. Emergex Vaccines
18. Versatope Therapeutics, Inc.
19. BIKEN Co., Ltd.
20. Gamma Vaccines Pty Ltd.
21. BiondVax Pharmaceuticals Ltd.
22. Hualan Biological Engineering Inc.
23. Shanghai Institute of Biological Products Co., Ltd.

The Report Analyses the Market on the Basis of Nationals and Presents the Forecast in Terms of Value and Volume for the Next 8 Years. Twenty-Seven Major Markets(27MM) Covered in the Report are as follows:

1. United States
2. Canada
3. Brazil
4. Germany
5. France
6. Italy
7. Spain
8. United Kingdom
9. Netherlands
10. Sweden
11. Denmark
12. Poland
13. Norway
14. Finland
15. Ireland
16. Belgium
17. Australia
18. New Zealand
19. Japan
20. China
21. India
22. South Korea
23. Thailand
24. Singapore
25. Hongkong
26. Malaysia
27. Indonesia

This Latest and Comprehensive th Global Influenza Vaccines Market Research Report 2024 provides:

Comprehensive research methodology of the global influenza vaccines market
Detailed and comprehensive market overview with important analyst insights
Insights into the market determinants stimulating the global influenza vaccines market
Analysis of the historical growth of the market size of the global influenza vaccines market from 2018 to 2023
The global influenza vaccines market size estimation and forecast from 2024 to 2032 and growth rate up to 2032
The market size of the 27 major influenza vaccines markets with eight years forecast
High-Level assessment of the overall persons being vaccinated with influenza vaccines
Scrutinizes the persons being vaccinated with influenza vaccines in the 27 major influenza vaccines markets with eight years forecast
Detailed assessment of the most recent happenings in the global influenza vaccines market
Comprehensive analysis of the regulatory framework including the approval process and an overview of the regulatory authorities in the United States, EU, and Japan
Provides key trends with respect to collaboration deals, merger & acquisitions, distribution, exclusive and licensing agreement
Detailed observations of the most recent clinical trials of the influenza vaccines
A comprehensive list of the key players along with the analysis of their current vaccines portfolios, promising vaccines in the clinical development, sales value analysis, and recent development
An insightful analysis of the emerging players along with the analysis of their promising vaccines in the clinical development, phase, platform technology, and recent development

This 2024 Report Helps Answer the Following Questions:

What is the current size of the global influenza vaccines market?
How big is the global market for influenza vaccines?
How much will this market be worth between 2024 and 2032?
How many persons being vaccinated with influenza vaccines globally during 2018 – 2032?
Which country is the leader in the global market for influenza vaccines?
How large is the market and what are the growth rates of the 27 most important markets for influenza vaccines?
What is the regulatory framework of the global influenza vaccines market?
What are the main drivers and challenges in the global influenza vaccines market?
What are the major deals happenings in the global influenza vaccines market?
Who are the top players and what are their activities, revenue, recent developments, and prospects?
Who are the emerging players?
What are some of the most prominent influenza vaccines currently in development?
What are the activities, phase, platform technology, and recent developments of the emerging players?
How will the industry develop in the forecast period 2024 – 2032?

1. Introduction
2. Research Methodology
3. Executive Summary
4. Global Number of Persons Vaccinated with Influenza Vaccines and Forecast (2018 – 2032)
5. Global Influenza Vaccines Market Revenue and Forecast (2018 – 2032)
6. Global Influenza Vaccines Market Share and Y–o–Y Growth (%): 6.1 Number of Persons Vaccinated with Influenza Vaccines Share, 2018 – 2032 (%); 6.2 Influenza Vaccines Market Share,2018 - 2032(%)
7. Global Influenza Vaccines Market Drivers and Challenges: 7.1 Market Drivers; 7.2 Market Challenges
8. Global Influenza Vaccines Market, By Geography (Volume and Value),2018 – 2032: 8.1 United States; 8.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027); 8.1.2 United States Influenza Vaccines Market Revenue (2018 – 2032); 8.2 Canada; 8.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027); 8.2.2 Canada Influenza Vaccines Market Revenue (2018 – 2032); 8.3 Germany; 8.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027); 8.3.2 Germany Influenza Vaccines Market Revenue (2018 – 2032); 8.4 France; 8.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027); 8.4.2 France Influenza Vaccines Market Revenue (2018 – 2032); 8.5 Italy; 8.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.5.2 Italy Influenza Vaccines Market Revenue (2018 – 2032); 8.6 Spain; 8.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.6.2 Spain Influenza Vaccines Market Revenue (2018 – 2032); 8.7 United Kingdom; 8.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.7.2 United Kingdom Influenza Vaccines Market Revenue (2018 – 2032); 8.8 Netherlands; 8.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.8.2 Netherlands Influenza Vaccines Market Revenue (2015 – 2027); 8.9 Sweden; 8.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.9.2 Sweden Influenza Vaccines Market Revenue (2018 – 2032); 8.10 Denmark; 8.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.10.2 Denmark Influenza Vaccines Market Revenue (2018 – 2032); 8.11 Poland; 8.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2015 – 2027); 8.11.2 Poland Influenza Vaccines Market Revenue (2018 – 2032); 8.12 Norway; 8.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.12.2 Norway Influenza Vaccines Market Revenue (2018 – 2032); 8.13 Finland; 8.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032 ); 8.13.2 Finland Influenza Vaccines Market Revenue (2018 – 2032); 8.14 Ireland; 8.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.14.2 Ireland Influenza Vaccines Market Revenue (2018 – 2032) 110; 8.15 Belgium; 8.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.15.2 Belgium Influenza Vaccines Market Revenue (2015 – 2027); 8.16 Australia; 8.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.16.2 Australia Influenza Vaccines Market Revenue (2018 – 2032); 8.17 New Zealand; 8.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.17.2 New Zealand Influenza Vaccines Market Revenue (2018 – 2032); 8.18 Japan; 8.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.18.2 Japan Influenza Vaccines Market Revenue (2018 – 2032); 8.19 Brazil; 8.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.19.2 Brazil Influenza Vaccines Market Revenue (2018 – 2032); 8.20 China; 8.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.20.2 China Influenza Vaccines Market Revenue (2018 – 2032); 8.21 India; 8.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.21.2 India Influenza Vaccines Market Revenue (2018 – 2032); 8.22 South Korea; 8.22.1 South Korea Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.22.2 South Korea Influenza Vaccines Market Revenue (2018 – 2032); 8.23 Thailand; 8.23.1 Thailand Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.23.2 Thailand Influenza Vaccines Market Revenue (2018 – 2032); 8.24 Singapore; 8.24.1 Singapore Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.24.2 Singapore Influenza Vaccines Market Revenue (2018 – 2032); 8.25 Hongkong; 8.25.1 Hongkong Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.25.2 Hongkong Influenza Vaccines Market Revenue (2018 – 2032); 8.26 Malaysia; 8.26.1 Malaysia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.26.2 Malaysia Influenza Vaccines Market Revenue (2018 – 2032); 8.27 Indonesia; 8.27.1 Indonesia Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.27.2 Indonesia Influenza Vaccines Market Revenue (2018 – 2032); 8.28 Rest of the World (ROW); 8.28.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2018 – 2032); 8.28.2 ROW Influenza Vaccines Market Revenue (2018 – 2032)
9. Recent Development in the Global Influenza Vaccines Market
10. Regulatory Framework of the Global Influenza Vaccines Market: 10.1 United States; 10.2 Europe; 10.3 Japan
11. Major Deals in the Global Influenza Vaccines Market: 11.1 Merger and Acquisitions; 11.2 Collaboration Deals; 11.3 Licensing Agreement; 11.4 Exclusive Agreement; 11.5 Distribution Agreement
12. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country: 12.1 Year 2023; 12.2 Year 2022
13. Key Companies Analysis: 13.1 Sanofi Pasteur; 13.1.1 Business Overview; 13.1.2 Influenza Vaccines Portfolio; 13.1.3 Influenza Vaccines Value Sales Analysis; 13.1.4 Promising Influenza Vaccines in the Clinical Development; 13.1.5 Recent Development; 13.2 GlaxoSmithKline (GSK); 13.2.1 Business Overview; 13.2.2 Influenza Vaccines Portfolio; 13.2.3 Influenza Vaccines Sales Value Analysis; 13.2.4 Recent Development; 13.3 Seqirus (CSL Limited); 13.3.1 Business Overview; 13.3.2 Influenza Vaccines Portfolios; 13.3.3 Influenza Vaccines Sales Value Analysis; 13.3.4 Promising Influenza Vaccines in the Clinical Development; 13.3.5 Recent Development; 13.4 AstraZeneca; 13.4.1 Business Overview; 13.4.2 Influenza Vaccines Portfolio; 13.4.3 Influenza Vaccines Sales Value Analysis; 13.4.4 Recent Development; 13.5 Gamma Vaccines Pty Ltd; 13.5.1 Business Overview; 13.5.2 Influenza Vaccines Portfolio; 13.5.3 Recent Development; 13.6 Hualan Biological Engineering Inc; 13.6.1 Business Overview; 13.6.2 Influenza Vaccines Portfolio; 13.6.3 Recent Development; 13.7 Shanghai Institute of Biological Products Co., Ltd.; 13.7.1 Business Overview; 13.7.2 Influenza Vaccines Portfolio; 13.7.3 Recent Development; 13.8 Mylan; 13.8.1 Business Overview; 13.8.2 Influenza Vaccines Portfolio; 13.8.3 Recent Development; 13.9 BioDiem; 13.9.1 Business Overview; 13.9.2 Influenza Vaccines Portfolio; 13.9.3 Recent Development; 13.10 BIKEN Co., Ltd.; 13.10.1 Business Overview; 13.10.2 Influenza Vaccine Portfolio; 13.10.3 Recent Development
14. Emerging Players: 14.1 Novavax; 14.1.1 Business Overview; 14.1.2 Promising Influenza Vaccines in the Clinical Development; 14.1.3 Recent Development; 14.2 BiondVax Pharmaceuticals Ltd.; 14.2.1 Business Overview; 14.2.2 Promising Influenza Vaccines in the Clinical Development; 14.2.3 Recent Development; 14.3 Medicago; 14.3.1 Business Overview; 14.3.2 Promising Influenza Vaccines in the Clinical Development; 14.3.3 Recent Development; 14.4 Moderna Inc; 14.4.1 Business Overview; 14.4.2 Promising Influenza Vaccines in the Clinical Development; 14.4.3 Recent Development; 14.5 Pneumagen; 14.5.1 Business Overview; 14.5.2 Promising Influenza Vaccines in the Clinical Development; 14.5.3 Recent Development; 14.6 Altimmune; 14.6.1 Business Overview; 14.6.2 Promising Influenza Vaccines in the Clinical Development; 14.6.3 Recent Development; 14.7 Daiichi Sankyo; 14.7.1 Business Overview; 14.7.2 Promising Influenza Vaccines in the Clinical Development; 14.7.3 Recent Development; 14.8 FluGen; 14.8.1 Business Overview; 14.8.2 Promising Influenza Vaccines in the Clinical Development; 14.8.3 Recent Development; 14.9 Imutex; 14.9.1 Business Overview; 14.9.2 Promising Vaccines in the Clinical Development; 14.9.3 Recent Development; 14.10 EpiVax; 14.10.1 Business Overview; 14.10.2 Promising Influenza Vaccines in the Clinical Development; 14.10.3 Recent Development; 14.11 Versatope Therapeutics, Inc.; 14.11.1 Business Overview; 14.11.2 Promising Influenza Vaccines in the Clinical Development; 14.11.3 Recent Development; 14.12 Emergex Vaccines; 14.12.1 Business Overview; 14.12.2 Promising Influenza Vaccines in the Clinical Development; 14.12.3 Recent Development; 14.13 Osivax; 14.13.1 Business Overview; 14.13.2 Promising Influenza Vaccines in the Clinical Development; 14.13.3 Recent Development
15. Appendix: 15.1 About DPI Research; 15.2 Glossary of Terms
List of Tables:: Table 6-1: Global Number of Persons Vaccinated with Influenza Vaccines Share (Percent),2018 – 2032; Table 6-2: Global Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent),2024 – 2032; Table 6-3: Global Influenza Vaccines Market Share (Percent),2018 – 2023; Table 6-4: Global Influenza Vaccines Market Share Forecast (Percent),2023 – 2032; Table 10-1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization; Table 10-2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization; Table 10-3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization; Table 11-1: Merger & Acquisitions in the Influenza Vaccines Market; Table 11-2: Collaboration Deal in the Influenza Vaccines Market; Table 11-3: Licensing Agreement in the Influenza Vaccines Market; Table 11-4: Exclusive Agreement in the Influenza Vaccines Market; Table 11-5: Distribution Agreement in the Influenza Vaccines Market; Table 13-1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development; Table 13-2: Seqirus Promising Influenza Vaccines in the Clinical Development; Table 14-1: Novavax Promising Influenza Vaccines in the Clinical Development; Table 14-2: Biondvax Promising Influenza Vaccines in the Clinical Development; Table 14-3: Medicago Promising Influenza Vaccines in the Clinical Development; Table 14-4: Moderna Promising Influenza Vaccines in the Clinical Development; Table 14-5: Pneumagen Promising Influenza Vaccines in the Clinical Development; Table 14-6: Altimmune Promising Influenza Vaccines in the Clinical Development; Table 14-7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development; Table 14-8: FluGen Promising Influenza Vaccines in the Clinical Development; Table 14-9: Imutex Promising Influenza Vaccines in the Clinical Development; Table 14-10: EpiVax Promising Influenza Vaccines in the Clinical Development; Table 14-11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
List of Figures:: Figure 4-1: Global Number of Persons Vaccinated with Influenza Vaccines (Thousand),2018 – 2023; Figure 4-2: Global Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand),2024 – 2032; Figure 5-1: Global Influenza Vaccines Market (Million US$),2018 – 2023; Figure 5-2: Global Influenza Vaccines Market Forecast (Million US$),2024 – 2032; Figure 8-1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-3: United States Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-4: United States Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-7: Canada Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-8: Canada Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-11: Germany Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-12: Germany Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-15: France Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-16: France Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-19: Italy Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-20: Italy Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-23: Spain Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-24: Spain Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-27: United Kingdom Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-31: Netherlands Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-35: Sweden Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-36: Sweden Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-39: Denmark Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-40: Denmark Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-43: Poland Influenza Vaccines Revenue Market (Million US$),2018 – 2023; Figure 8-44: Poland Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-47: Norway Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-48: Norway Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-51: Finland Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-52: Finland Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-55: Ireland Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-56: Ireland Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-59: Belgium Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-60: Belgium Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-63: Australia Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-64: Australia Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-67: New Zealand Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-71: Japan Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-72: Japan Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2023 – 2032; Figure 8-75: Brazil Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-76: Brazil Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8 77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-79: China Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-80: China Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-83: India Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-84: India Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-85: South Korea Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-86: South Korea Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-87: South Korea Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-88: South Korea Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-89: Thailand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-90: Thailand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-91: Thailand Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-92: Thailand Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-93: Singapore Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-94: Singapore Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-95: Singapore Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-96: Singapore Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-97: Hongkong Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-98: Hongkong Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-99: Hongkong Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-100: Hongkong Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-101: Malaysia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-102: Malaysia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-103: Malaysia Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-104: Malaysia Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-105: Indonesia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-106: Indonesia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-107: Indonesia Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-108: Indonesia Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 8-109: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 – 2023; Figure 8-110: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 – 2032; Figure 8-111: ROW Influenza Vaccines Market Revenue (Million US$),2018 – 2023; Figure 8-112: ROW Influenza Vaccines Market Revenue Forecast (Million US$),2024 – 2032; Figure 13-1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2018 – 2023; Figure 13-2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2024 – 2032; Figure 13-3: GSK Influenza Vaccines Net Sales Value (Million US$),2018 – 2023; Figure 13-4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2024 – 2032; Figure 13-5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2018 – 2023; Figure 13-6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2024 – 2032; Figure 13-7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2018 – 2023; Figure 13-8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2024 – 2032